for treating von Hippel-Lindau (VHL) disease in adults:

• who need treatment for VHL‑associated renal cell carcinomas, central nervous system hemangioblastomas or pancreatic neuroendocrine tumours, and

• when localised procedures are unsuitable or undesirable.

Targeted-release budesonide can be used as an option to treat primary immunoglobulin A nephropathy (IgAN) in adults when:

they have:

• • a urine protein-to-creatinine ratio (UPCR) of 90 mg/mmol or more or
  • a protein excretion of 1.0 g/day or more, and

it is used as an add-on to optimised standard care that includes, unless contraindicated:

• the highest tolerated licensed dose of renin-angiotensin system inhibitors (RASi) or
• a dual endothelin angiotensin-receptor antagonist (DEARA) 

(NICE TA1128)

Commissioned by NHSE

For treating activated phosphoinositide 3-kinase delta syndrome (APDS) in people 12 years and over (NICE HST33)

For treating HLA-A*02:01-positive unresectable or metastatic uveal melanoma in adults (TA1027)